Home > Insider Trading > Filing (0001654954-25-007107)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
911216	Palatin Technologies Inc	PTN	Pharmaceutical Preparations (2834)	954078884

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1103883	T Stephen Wills	Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury NJ 08512	Executive Vp And Cfo/Coo	No	No	No	No

Transaction Summary

Purchased:	1,500 shares	Avg. Price: $150,000.00	Total Value: $225,000,000.00
Number of Shares After Transactions:	1,640,756 shares

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Series D Preferred Stock	Acquisiton	2025-06-13	1,500	$150,000.00	1,640,756	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series I warrants	Acquisiton	2025-06-13	2,727,272	$0.00	2,727,272	$0.11

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
3,017,838			No	4	P	Direct

Footnotes

Each share of Series D Convertible Preferred Stock has a stated value of $100 per share, and is convertible to common stock at an initial conversion price of $0.11 per share, for a total of 1,363,636 shares of common stock. The Series D Preferred Stock and Series I common stock purchase warrants were sold at a combined offering price of $0.11 per share of common stock obtainable upon conversion of the Series D Convertible Preferred Stock.
The Series I warrants are exercisable on or after the date that approval is obtained from the Issuer's stockholders as may be required by the NYSE American (or any successor entity) (the "Stockholder Approval Date"), and will expire on the five-year anniversary of the Stockholder Approval Date, subject to the terms and conditions contained in such Series I warrant.